Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 91.75 EUR -0.03% Market Closed
Market Cap: 116.4B EUR
Have any thoughts about
Sanofi SA?
Write Note

Sanofi SA
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sanofi SA
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Sanofi SA
PAR:SAN
Accounts Receivables
€8.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Accounts Receivables
€719.2m
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
10%
Vetoquinol SA
PAR:VETO
Accounts Receivables
€93.1m
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
4%
Virbac SA
PAR:VIRP
Accounts Receivables
€222.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Accounts Receivables
€77.7m
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
0%
Medincell SA
PAR:MEDCL
Accounts Receivables
€1.5m
CAGR 3-Years
26%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Sanofi SA
Glance View

Market Cap
114.8B EUR
Industry
Pharmaceuticals

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SAN Intrinsic Value
110.89 EUR
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Sanofi SA's Accounts Receivables?
Accounts Receivables
8.5B EUR

Based on the financial report for Sep 30, 2024, Sanofi SA's Accounts Receivables amounts to 8.5B EUR.

Back to Top